FrancophonIA/ELRC3.0 huggingface dataset:
English: The full EPAR for Celsentri can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Celsentri kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The safety profile of Celsentri is considered acceptable and no major concerns have been identified.
Estonian: Celsentri ohutusprofiili peetakse vastuvõetavaks ja suuri ohutusprobleeme ei ole tuvastatud.
English: Other information about Celsentri
Estonian: Muu teave Celsentri kohta
English: Celsentri is available as tablets (25, 75, 150 and 300 mg) and as a liquid (20 mg/ml) to be taken by mouth.
Estonian: Celsentrit turustatakse tablettidena (25, 75, 150 ja 300 mg) ja suukaudse suspensioonina (20 mg/ml).
English: What is Celsentri and what is it used for?
Estonian: Mis on Celsentri ja milleks seda kasutatakse?
English: Celsentri does not cure HIV infection or AIDS, but it may hold off the damage to the immune system and the development of infections and diseases associated with AIDS.
Estonian: Celsentri ei ravi HIV-infektsiooni ega AIDSi välja, kuid võib immuunsüsteemi kahjustumist ning AIDSiga seotud infektsioonide ja haiguste tekkimist edasi lükata.
English: Patients who have reduced kidney function may need to take Celsentri less frequently.
Estonian: Vähenenud neerutalitlusega patsientidel võib olla vaja võtta Celsentrit harvem.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) therefore decided that Celsentri's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Seetõttu otsustas inimravimite komitee, et Celsentri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Similar results were also seen when looking at the patients who continued treatment with Celsentri 300 mg twice a day for 48 weeks.
Estonian: Samalaadne tulemus oli ka patsientidel, kes jätkasid ravi Celsentriga 300 mg kaks korda ööpäevas 48 nädala jooksul.
English: Celsentri tablets must not be used in patients who are hypersensitive (allergic) to peanut and soya.
Estonian: Celsentri tablette ei tohi kasutada patsiendid, kes on maapähkli või soja suhtes ülitundlikud (allergilised).
English: Why is Celsentri approved?
Estonian: Miks Celsentri heaks kiideti?
English: In adults, the recommended dose is 150, 300 or 600 mg twice a day, depending on the other medicines that the patient is taking.
Estonian: Täiskasvanutel on soovitatav annus 150 mg, 300 mg või 600 mg kaks korda ööpäevas, olenevalt teistest samaaegselt kasutatavatest ravimitest.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Celsentri have been included in the summary of product characteristics and the package leaflet.
Estonian: Celsentri ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: All of the patients also took ‘optimised background therapy' (a combination of other HIV medicines chosen for each patient to increase the chances of reducing the levels of HIV in the blood).
Estonian: Kõik patsiendid kasutasid ka optimeeritud foonravi (muude viirusravimite kombinatsioon, mis valiti igale patsiendile individuaalselt, et suurendada võimalust vähendada HIV-sisaldust veres).
English: In the studies Celsentri was compared with placebo (a dummy treatment).
Estonian: Uuringutes võrreldi Celsentrit platseeboga (näiv ravim).
English: The most common side effects with Celsentri (which may affect up to 1 in 10 people) are nausea (feeling sick), diarrhoea, fatigue (tiredness) and headache.
Estonian: Celsentri kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on iiveldus, kõhulahtisus, väsimus ja peavalu.
English: What are the risks associated with Celsentri?
Estonian: Mis riskid Celsentriga kaasnevad?
English: Celsentri contains the active substance maraviroc.
Estonian: Celsentri sisaldab toimeainena maravirokit.
English: Based on these data, effectiveness is expected to be similar in children and adults.
Estonian: Neile andmetele tuginedes on ravimi efektiivsus lastel eeldatavasti samasugune kui täiskasvanuil.
English: It is not intended to provide practical advice on how to use Celsentri.
Estonian: Hindamisaruandes ei anta Celsentri kasutamise praktilisi nõuandeid.
English: Before treatment, the doctor must check that the patient's blood only shows infection with CCR5-tropic virus.
Estonian: Enne ravi alustamist peab arst uurima, kas patsiendi vereanalüüs näitab üksnes CCR5-troopilise viiruse nakkust.
English: CCR5-tropic HIV uses this protein to enter the cells.
Estonian: CCR5-troopiline HIV kasutab seda valku rakkudesse sisenemiseks.
English: How is Celsentri used?
Estonian: Kuidas Celsentrit kasutatakse?
English: The active substance in Celsentri, maraviroc, is a ‘CCR5 antagonist'.
Estonian: Celsentri toimeaine maravirok on CCR5-antagonist.
English: Celsentri cannot work against viruses that attach to another protein called CXCR4, or when it can attach to both CCR5 and CXCR4.
Estonian: Celsentri ei toimi viiruste vastu, mis kinnituvad valgule CXCR4, ega viiruste vastu, mis võivad kinnituda mõlemale, CCR5-le ja CXCR4-le.
English: Celsentri can only be obtained with a prescription and treatment should be started by a doctor who has experience in the management of HIV infection.
Estonian: Celsentri on retseptiravim ja ravi peab alustama HIV-infektsiooni ravis kogenud arst.
English: Celsentri is used in combination with other HIV medicines, and only in patients who have been treated for HIV infection before and only when the HIV-1 they are infected with is ‘CCR5-tropic', which is determined by a blood test.
Estonian: Celsentrit kasutatakse koos teiste HIV-ravimitega üksnes patsientidel, kes on varem saanud HIVnakkuse vastast ravi, ja üksnes juhul, kui HIV-1 on CCR5-troopiline, mis määratakse kindlaks vereanalüüsiga.
English: This is a summary of the European public assessment report (EPAR) for Celsentri.
Estonian: See on ravimi Celsentri Euroopa avaliku hindamisaruande kokkuvõte.
English: Celsentri used in combination with other HIV medicines has been shown to be effective at reducing the levels of HIV in the blood in adults, and similar effects are expected in children.
Estonian: On tõendatud, et koos teiste HIV-ravimitega kasutatav Celsentri on täiskasvanutel vere HIV-sisalduse vähendamisel efektiivne, ja sama toimet eeldatakse ka lastel.
English: For more information about treatment with Celsentri, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Celsentriga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: In children, the dose is based on body weight.
Estonian: Lastel määratakse annus kehakaalu alusel.
English: Looking at the results of the two studies taken together, the levels of HIV in the blood had fallen by an average of 99% after 24 weeks in the patients adding Celsentri to optimised background therapy, compared with 90% in those adding placebo.
Estonian: Arvestades kahe uuringu tulemusi koos, vähenes 24 nädala järel patsientidel, kelle optimeeritud foonravile lisati Celsentrit, vere HIV-sisaldus keskmiselt 99% võrra, võrreldes 90%-ga patsientidel, kelle ravile lisati platseebot.
English: The proportion of patients who had undetectable levels of HIV in their blood after 24 weeks was about 45% with Celsentri compared to 23% with placebo.
Estonian: Patsiente, kelle veres 24 nädala järel HIVi ei tuvastatud, oli Celsentri rühmas ligikaudu 45% ja platseeborühmas 23%.
English: For practical information about using Celsentri, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Celsentri kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: By attaching itself to the protein, Celsentri prevents the virus from entering the cells.
Estonian: Valgule kinnitudes takistab Celsentri viiruse sisenemist rakkudesse.
English: As HIV can only reproduce itself within cells, Celsentri, taken in combination with other HIV medicines, reduces the level of CCR5-tropic HIV, and keeps it at a low level.
Estonian: Et HIV paljuneb ainult rakkudes, vähendab koos teiste HIV-ravimitega manustatav Celsentri CCR5-troopilise HIVi kogust ja hoiab selle sisalduse väikese.
English: Additional data indicate that Celsentri given at a suitable dose to children is handled by their body in the same way as in adults.
Estonian: Lisaandmed näitavad, et lapse organism käitleb Celsentri sobivat annust samal viisil kui täiskasvanu organism.
English: It blocks the CCR5 protein on the surface of the cells in the body that HIV infects.
Estonian: See blokeerib valgu CCR5, mida leidub organismis HIV-nakkusega rakkude pinnal.
English: Celsentri is an HIV medicine used to treat patients from 2 years of age and weighing at least 10 kg who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Estonian: Celsentri on HIV-ravim, mida kasutatakse omandatud immuunpuudulikkuse sündroomi (AIDS) põhjustava inimese immuunpuudulikkuse 1. tüüpi viiruse (HIV-1) infektsiooni raviks patsientidel, kes on vähemalt 2-aastased ja kehamassiga vähemalt 10 kg.
English: What benefits of Celsentri have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Celsentri kasulikkus?
English: How does Celsentri work?
Estonian: Kuidas Celsentri toimib?
English: For the full list of all side effects reported with Celsentri, see the package leaflet.
Estonian: Celsentri kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Celsentri has been shown to be effective at reducing the levels of HIV in the blood in two main studies involving a total of 1,076 mostly adult patients with CCR5-tropic HIV infection.
Estonian: Kahes põhiuuringus kokku 1076 enamasti täiskasvanud patsiendil, kel oli CCR5-troopiline HIV-nakkus, tõendati Celsentri efektiivsust vere HIV-sisalduse vähendamisel.
English: This means that the virus, when infecting a cell, attaches to a specific protein called CCR5 on the surface of the cell.
Estonian: CCR5-troopiline tähendab, et rakku nakatav viirus kinnitub raku pinnal spetsiifilisele CCR5-valgule.
English: Aprovel irbesartan
Estonian: Aprovel irbesartaan
English: The European Commission granted a marketing authorisation valid throughout the European Union for Aprovel on 27 August 1997.
Estonian: Euroopa Komisjon andis Aproveli müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 27. augustil 1997.
English: The full EPAR for Aprovel can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Aproveli kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Other information about Aprovel
Estonian: Muu teave Aproveli kohta
English: What is Aprovel?
Estonian: Mis on Aprovel?
English: The usual recommended dose of Aprovel is 150 mg once a day.
Estonian: Aproveli tavaline soovitatav annus on 150 mg üks kord ööpäevas.
English: Aprovel was used for two years or more.
Estonian: Aproveli manustati vähemalt kahe aasta jooksul.
English: Why has Aprovel been approved?
Estonian: Miks Aprovel heaks kiideti?
English: The CHMP decided that Aprovel's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Aproveli kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Aprovel in combination with aliskirencontaining medicines (used to treat essential hypertension) must not be used in patients with diabetes, or moderate or severe kidney impairment.
Estonian: Koos aliskireeni sisaldavate ravimitega (essentsiaalse hüpertensiooni ravimid) ei tohi Aproveli kasutada diabeediga või mõõduka või raske neerupuudulikkusega patsiendid.
English: What is the risk associated with Aprovel?
Estonian: Mis riskid Aproveliga kaasnevad?
English: For more information about treatment with Aprovel, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Aproveliga toimuva ravi kohta lisateavet, lugege pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Aprovel is a medicine that contains the active substance irbesartan.
Estonian: Aprovel on ravim, mis sisaldab toimeainena irbesartaani.
English: For the treatment of kidney disease, Aprovel was studied in two large studies involving a total of 2,326 patients with type 2 diabetes.
Estonian: Aproveli toimet neeruhaiguste ravis uuriti kahes ulatuslikus uuringus, milles osales 2326 II tüüpi diabeediga patsienti.
English: This is a summary of the European public assessment report (EPAR) for Aprovel.
Estonian: See on ravimi Aprovel Euroopa avaliku hindamisaruande kokkuvõte.
English: In this study, Aprovel was compared with placebo and with amlodipine.
Estonian: Selles uuringus võrreldi Aproveli toimet platseebo ja amlodipiini toimega.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Aprovel.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: The most common side effect with Aprovel (seen in more than 1 patient in 10) is hyperkalaemia (high blood potassium levels).
Estonian: Aproveli kõige sagedam kõrvalnäht (esinenud enam kui 1 patsiendil 10st) on hüperkaleemia (vere liigne kaaliumisisaldus).
English: Aprovel was compared with placebo (a dummy treatment) in 712 patients and with other medicines for hypertension (atenolol, enalapril or amlodipine) in 823 patients.
Estonian: 712 patsiendil võrreldi Aproveli toimet platseebo (näiva ravimi) toimega ja 823 patsiendil teiste kõrgvererõhuravimite (atenolooli, enalapriili, amlodipiini) toimega.
English: Aprovel is used in adults who have essential hypertension (high blood pressure).
Estonian: Aproveli kasutatakse täiskasvanutel, kellel on essentsiaalne hüpertensioon (kõrgvererõhutõbi).
English: For the full list of all side effects reported with Aprovel, see the package leaflet.
Estonian: Aproveli kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The second study looked at whether Aprovel increased the time taken until the patients' blood creatinine levels had doubled (a marker of kidney disease), until they needed a kidney transplant or dialysis, or until they died.
Estonian: Teises uuringus jälgiti, kas Aprovel pikendab aega, mille jooksul patsiendil vere kreatiniinisisaldus (neeruhaiguse marker) kahekordistub või kuni patsient vajab neerusiirdamist või dialüüsi, või aega patsiendi surmani.
English: The active substance in Aprovel, irbesartan, is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II.
Estonian: Aproveli toimeaine irbesartaan on angiotensiin II retseptori antagonist, mis blokeerib organismi hormooni angiotensiin II toime.
English: What benefit has Aprovel shown during the studies?
Estonian: Milles seisneb uuringute põhjal Aproveli kasulikkus?
English: Aprovel is also used to treat kidney disease in adults with hypertension and type 2 diabetes.
Estonian: Aproveli kasutatakse ka neeruhaiguste raviks hüpertensiooniga ja II tüüpi diabeediga täiskasvanutel.
English: Aprovel was originally studied in 11 trials for its effects on blood pressure.
Estonian: Aproveli toimet vererõhule uuriti esialgu 11 uuringus.
English: In the second kidney disease study, Aprovel reduced the relative risk of a doubling of blood creatinine levels, needing a kidney transplant or dialysis, or death during the study by 20% in comparison with placebo.
Estonian: Teises neeruhaiguste uuringus vähendas Aprovel vere kreatiniinisisalduse kahekordistumise, neerusiirdamise või dialüüsi vajaduse või surma suhtelist riski platseeboga võrreldes 20% võrra.
English: Aprovel must not be used in people who are hypersensitive (allergic) to irbesartan or any of the other ingredients.
Estonian: Aproveli ei tohi kasutada patsiendid, kes on irbesartaani või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: In patients with hypertension and type 2 diabetes, Aprovel is added to some other treatments for hypertension.
Estonian: Kõrgvererõhuga ja II tüüpi diabeediga patsientidel kasutatakse Aproveli lisaks teatud teistele kõrgvererõhuravimitele.
English: How does Aprovel work?
Estonian: Kuidas Aprovel toimib?
English: The medicine can only be obtained with a prescription.
Estonian: Aprovel on retseptiravim.
English: In the blood pressure studies, Aprovel was more effective than placebo at reducing diastolic blood pressure and had similar effects to the other medicines for hypertension.
Estonian: Vererõhu uuringutes täheldati, et Aprovel alandab diastoolset vererõhku paremini kui platseebo ning Aproveli toime sarnaneb teiste kõrgvererõhuravimite toimega.
English: How is Aprovel used?
Estonian: Kuidas Aproveli kasutatakse?
English: How has Aprovel been studied?
Estonian: Kuidas Aproveli uuriti?
English: In the first kidney disease study, Aprovel was more effective than placebo at reducing the risk of developing kidney damage as measured by protein excretion.
Estonian: Esimeses neeruhaiguste uuringus oli Aprovel neerukahjustuse (hinnati valgueritumise alusel) tekkeriski vähendamisel efektiivsem kui platseebo.
English: What is Aprovel used for?
Estonian: Milleks Aproveli kasutatakse?
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 7 December 2011
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE/MÜÜGILOA UUENDAMISE KUUPÄEV 7. detsember 2011
English: It is important to keep taking Ipreziv every day.
Estonian: Iprezivi on oluline võtta igapäevaselt.
English: Therefore, Ipreziv should not be given to children or adolescents.
Estonian: Seepärast ei tohiks Iprezivi anda lastele või noorukitele.
English: (It is also better to avoid Ipreziv in early pregnancy - see pregnancy section).
Estonian: (Samuti on parem Iprezivi kasutamisest hoiduda raseduse varajases staadiumis - vt lõiku Rasedus).
English: The possibility of similar effects cannot be excluded with Ipreziv.
Estonian: Sarnaste mõjude võimalust ei saa Iprezivi puhul välistada.
English: Therefore do not stop taking Ipreziv without first talking to your doctor about alternative treatment options.
Estonian: Seega ärge lõpetage Iprezivi võtmist eelnevalt oma arstiga alternatiivsetest ravivõimalustest rääkimata.
English: If you stop taking Ipreziv, your blood pressure may increase again.
Estonian: Kui te lõpetate Iprezivi võtmise, võib teie vererõhk uuesti tõusta.
English: See also information under the heading “Do not take Ipreziv”.
Estonian: Vt ka teavet lõigus „Ärge kasutage Ipreziv”
English: Older people (65 years and over)
Estonian: Eakad (vanus 65 aastat ja vanemad)
English: Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Estonian: Palun informeerige oma arsti või apteekrit, kui te kasutate või olete hiljuti kasutanud mingeid muid ravimeid, kaasa arvatud ilma retseptita ostetud ravimid.
English: However some people may feel tired or dizzy when taking Ipreziv and if this happens to you, do not drive or use any tools or machines.
Estonian: Siiski võivad mõned inimesed tunda Iprezivi kasutamise ajal väsimust või peapööritust ja kui see juhtub teiega, ärge juhtige autot või kasutage masinaid või mehhanisme.
English: Other medicines and Ipreziv
Estonian: Muud ravimid ja Ipreziv
English: If you stop taking Ipreziv
Estonian: Kui te lõpetate Iprezivi võtmise
English: Your doctor may increase this dose to a maximum of 80 mg once a day depending on blood pressure response.
Estonian: Teie arst võib suurendada doosi maksimaalselt kuni 80 mg üks kord päevas, olenevalt vererõhu vastusest.
English: Like all medicines, Ipreziv can cause side effects, although not everybody gets them.
Estonian: Nagu kõik ravimid, võib ka Ipreziv põhjustada kõrvaltoimeid, kuigi kõigil neid ei teki.
English: Ipreziv can affect the way some other medicines work and some medicines can have an effect on Ipreziv.
Estonian: Ipreziv võib mõjutada teiste ravimite toimet ning mõningatel ravimitel võib olla mõju Iprezivile.
English: There is currently no experience on the use of Ipreziv in patients who have recently undergone kidney transplantation.
Estonian: Käesoleval hetkel puuduvad kogemused Iprezivi kasutamisest patsientide ravis, kes on hiljuti läbinud neerusiirdamise.
English: M-I and M-II do not contribute to the pharmacologic activity of Ipreziv.
Estonian: M-I ja M-II ei toeta Iprezivi farmakoloogilist aktiivsust.
English: The safety and efficacy of Ipreziv in children and adolescents 0 to < 18 years have not yet been established.
Estonian: Iprezivi ohutus ning efektiivsus lastel ja noorukitel vanuses 0 kuni 18 aastat ei ole veel tõestatud.
English: Pharmacotherapeutic group: Angiotensin II antagonists, plain ATC Code: C09CA09
Estonian: Farmakoterapeutiline grupp: angiotensiin II antagonistid ATC-kood: C09CA09
English: - The usual starting dose is 40 mg once a day.
Estonian: - Tavapärane algdoosi tase on 40 mg üks kord päevas.
English: Your doctor may need to change your dose and/or to take other precautions if you are taking an ACE-inhibitor or aliskiren (see also information under the headings “Do not take Ipreziv” and “Warnings and precautions”).
Estonian: Teie arst võib muuta teie ravimi annust ja/või rakendada teisi ettevaatusabinõusid: Kui te võtate AKE-inhibiitorit või aliskireeni (vt ka teavet lõikudes „Ärge kasutage Ipreziv“ ja „Hoiatused ja ettevaatusabinõud”)
English: o an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems.
Estonian: o AKE-inhibiitor (näiteks enalapriil, lisinopriil, ramipriil), eriti kui teil on suhkurtõvest tingitud neeruprobleemid
English: Takeda Ireland Limited, Bray Business Park, Kilruddery, Co. Wicklow, Ireland
Estonian: Takeda Ireland Limited, Bray Business Park, Kilruddery, Co. Wicklow, Iirimaa
English: Therefore, the use of Ipreziv is not recommended in these patients.
Estonian: Seetõttu ei ole Iprezivi kasutamine nendel patsientidel soovitatav.
English: Your doctor will normally advise you to stop taking Ipreziv before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Ipreziv.
Estonian: Tavaliselt soovitab arst lõpetada Iprezivi kasutamise enne rasestumist või niipea kui teile saab teatavaks, et olete rase, ning kirjutab teile Iprezivi asemel välja mõne muu ravimi.
English: Contents of the pack and other information
Estonian: PAKENDI SISU JA MUU TEAVE
English: Ipreziv had a lower incidence of cough (1.2%) compared with ramipril (8.2%).
Estonian: Iprezivi puhul esines köha vähem (1,2%), kui ramipriili puhul (8,2%).
English: The frequency of this event is highest when amlodipine is taken alone.
Estonian: Selle kõrvaltoime esinemissagedus on kõrgeim kui manustatakse ainult amlodipiini.
English: The European Medicines Agency has deferred the obligation to submit the results of studies with Ipreziv in one or more subsets of the paediatric population in hypertension (see section 4.2 for information on paediatric use).
Estonian: Euroopa Ravimiamet on peatanud kohustuse esitada Iprezivi kohta läbi viidud uuringute tulemusi ühe või mitme laste alarühma kohta hüpertensiooni korral (vt lõik 4.2 informatsioon kasutamisel pediaatrias).
English: WHAT YOU NEED TO KNOW BEFORE YOU TAKE IPREZIV
Estonian: MIDA ON VAJA TEADA ENNE IPREZIVI KASUTAMIST